Literature DB >> 20379381

Indications of rituximab in autoimmune diseases.

Iñaki Sanz1.   

Abstract

Entities:  

Year:  2009        PMID： 20379381      PMCID： PMC2850537          DOI： 10.1016/j.ddstr.2009.10.001

Source DB:  PubMed          Journal:  Drug Discov Today Ther Strateg        ISSN： 1740-6773


× No keyword cloud information.
  46 in total

Review 1.  Translational Mini-Review Series on B Cell-Directed Therapies: The pathogenic role of B cells in autoantibody-associated autoimmune diseases--lessons from B cell-depletion therapy.

Authors:  M J Leandro; I de la Torre
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

Review 2.  Cytokine-producing B lymphocytes-key regulators of immunity.

Authors:  Frances E Lund
Journal:  Curr Opin Immunol       Date:  2008-04-15       Impact factor: 7.486

3.  A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Rachel B Jones; Alastair J Ferraro; Afzal N Chaudhry; Paul Brogan; Alan D Salama; Kenneth G C Smith; Caroline O S Savage; David R W Jayne
Journal:  Arthritis Rheum       Date:  2009-07

4.  Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes.

Authors:  J C Edwards; G Cambridge
Journal:  Rheumatology (Oxford)       Date:  2001-02       Impact factor: 7.580

5.  Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Karina A Keogh; Mark E Wylam; John H Stone; Ulrich Specks
Journal:  Arthritis Rheum       Date:  2005-01

6.  Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies.

Authors:  E Keystone; P Emery; C G Peterfy; P P Tak; S Cohen; M C Genovese; M Dougados; G R Burmester; M Greenwald; T K Kvien; S Williams; D Hagerty; M W Cravets; T Shaw
Journal:  Ann Rheum Dis       Date:  2008-04-03       Impact factor: 19.103

Review 7.  Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases.

Authors:  Manuel Ramos-Casals; M J Soto; M J Cuadrado; M A Khamashta
Journal:  Lupus       Date:  2009-08       Impact factor: 2.911

8.  Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial.

Authors:  Kathleen Hawker; Paul O'Connor; Mark S Freedman; Peter A Calabresi; Jack Antel; Jack Simon; Stephen Hauser; Emmanuelle Waubant; Timothy Vollmer; Hillel Panitch; Jiameng Zhang; Peter Chin; Craig H Smith
Journal:  Ann Neurol       Date:  2009-10       Impact factor: 10.422

9.  Disease activity-guided rituximab therapy in rheumatoid arthritis: the effects of re-treatment in initial nonresponders versus initial responders.

Authors:  Rogier M Thurlings; Koen Vos; Daniëlle M Gerlag; Paul P Tak
Journal:  Arthritis Rheum       Date:  2008-12

10.  Safety of biological therapies following rituximab treatment in rheumatoid arthritis patients.

Authors:  M C Genovese; F C Breedveld; P Emery; S Cohen; E Keystone; E L Matteson; Y Baptiste; A Chai; L Burke; W Reiss; M Sweetser; T M Shaw
Journal:  Ann Rheum Dis       Date:  2009-01-20       Impact factor: 19.103
View more
  8 in total

Review 1.  Rationale for B cell targeting in SLE.

Authors:  Iñaki Sanz
Journal:  Semin Immunopathol       Date:  2014-04-25       Impact factor: 9.623

2.  An open-label trial of rituximab therapy in pulmonary alveolar proteinosis.

Authors:  M S Kavuru; A Malur; I Marshall; B P Barna; M Meziane; I Huizar; H Dalrymple; R Karnekar; M J Thomassen
Journal:  Eur Respir J       Date:  2011-04-08       Impact factor: 16.671

Review 3.  Hepatitis B reactivation in the setting of chemotherapy and immunosuppression - prevention is better than cure.

Authors:  Venessa Pattullo
Journal:  World J Hepatol       Date:  2015-05-08

4.  Rituximab and biosimilars - equivalence and reciprocity.

Authors:  Zaina P Qureshi; Jametta S Magwood; Sarveshwari Singh; Charles L Bennett
Journal:  Biosimilars       Date:  2013-06-14

Review 5.  Prevention of Hepatitis B reactivation in the setting of immunosuppression.

Authors:  Venessa Pattullo
Journal:  Clin Mol Hepatol       Date:  2016-06-13

Review 6.  Rituximab in kidney disease and transplant.

Authors:  Kajal Chauhan; Anita A Mehta
Journal:  Animal Model Exp Med       Date:  2019-03-26

7.  Rituximab induced acute thrombocytopenia in a patient with systemic lupus erythematosus: a case report.

Authors:  Jevon Yudhishdran; Jeyalakshmy Sivakumar; Mitrakrishnan Rayno Navinan; Sareesh Bandapatti
Journal:  J Med Case Rep       Date:  2021-07-08

8.  International standards for monoclonal antibodies to support pre- and post-marketing product consistency: Evaluation of a candidate international standard for the bioactivities of rituximab.

Authors:  Sandra Prior; Simon E Hufton; Bernard Fox; Thomas Dougall; Peter Rigsby; Adrian Bristow
Journal:  MAbs       Date:  2017-11-03       Impact factor: 5.857
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.